Correction: Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia (Leukemia, (2022), 36, 4, (1171-1175), 10.1038/s41375-021-01485-x)

Jeff P. Sharman; Miklos Egyed; Wojciech Jurczak; Alan Skarbnik; John M. Pagel; Ian W. Flinn; Manali Kamdar; Talha Munir; Renata Walewska; Gillian Corbett; Laura Maria Fogliatto; Yair Herishanu; Versha Banerji; Steven Coutre; George Follows; Patricia Walker; Karin Karlsson; Paolo Ghia; Ann Janssens; Florence Cymbalista; Jennifer A. Woyach; Emmanuelle Ferrant; William G. Wierda; Veerendra Munugalavadla; Ting Yu; Min Hui Wang; John C. Byrd

doi:10.1038/s41375-024-02487-1

Correction: Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia (Leukemia, (2022), 36, 4, (1171-1175), 10.1038/s41375-021-01485-x)

Jeff P. Sharman^*, Miklos Egyed, Wojciech Jurczak, Alan Skarbnik, John M. Pagel, Ian W. Flinn, Manali Kamdar, Talha Munir, Renata Walewska, Gillian Corbett, Laura Maria Fogliatto, Yair Herishanu, Versha Banerji, Steven Coutre, George Follows, Patricia Walker, Karin Karlsson, Paolo Ghia, Ann Janssens, Florence CymbalistaJennifer A. Woyach, Emmanuelle Ferrant, William G. Wierda, Veerendra Munugalavadla, Ting Yu, Min Hui Wang, John C. Byrd

^*Corresponding author for this work

Research output: Contribution to journal › Comment/debate

1 Scopus citations

Abstract

Correction to: Leukemiahttps://doi.org/10.1038/s41375-021-01485-x, published online 01 January 2022 The wrong Supplementary file was originally published with this article; it has now been replaced with the correct file. The original article has been corrected.

Original language	English
Pages (from-to)	529
Number of pages	1
Journal	Leukemia
Volume	39
Issue number	2
DOIs	https://doi.org/10.1038/s41375-024-02487-1
State	Published - Feb 2025
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/s41375-024-02487-1

Fingerprint

Dive into the research topics of 'Correction: Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia (Leukemia, (2022), 36, 4, (1171-1175), 10.1038/s41375-021-01485-x)'. Together they form a unique fingerprint.

Cite this

Sharman, J. P., Egyed, M., Jurczak, W., Skarbnik, A., Pagel, J. M., Flinn, I. W., Kamdar, M., Munir, T., Walewska, R., Corbett, G., Fogliatto, L. M., Herishanu, Y., Banerji, V., Coutre, S., Follows, G., Walker, P., Karlsson, K., Ghia, P., Janssens, A., ... Byrd, J. C. (2025). Correction: Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia (Leukemia, (2022), 36, 4, (1171-1175), 10.1038/s41375-021-01485-x). Leukemia, 39(2), 529. https://doi.org/10.1038/s41375-024-02487-1

Sharman, Jeff P. ; Egyed, Miklos ; Jurczak, Wojciech et al. / Correction : Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia (Leukemia, (2022), 36, 4, (1171-1175), 10.1038/s41375-021-01485-x). In: Leukemia. 2025 ; Vol. 39, No. 2. pp. 529.

@article{042dccba8b194cc9b89770cc2a4e22dc,

title = "Correction: Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-na{\"i}ve chronic lymphocytic leukemia (Leukemia, (2022), 36, 4, (1171-1175), 10.1038/s41375-021-01485-x)",

abstract = "Correction to: Leukemiahttps://doi.org/10.1038/s41375-021-01485-x, published online 01 January 2022 The wrong Supplementary file was originally published with this article; it has now been replaced with the correct file. The original article has been corrected.",

author = "Sharman, {Jeff P.} and Miklos Egyed and Wojciech Jurczak and Alan Skarbnik and Pagel, {John M.} and Flinn, {Ian W.} and Manali Kamdar and Talha Munir and Renata Walewska and Gillian Corbett and Fogliatto, {Laura Maria} and Yair Herishanu and Versha Banerji and Steven Coutre and George Follows and Patricia Walker and Karin Karlsson and Paolo Ghia and Ann Janssens and Florence Cymbalista and Woyach, {Jennifer A.} and Emmanuelle Ferrant and Wierda, {William G.} and Veerendra Munugalavadla and Ting Yu and Wang, {Min Hui} and Byrd, {John C.}",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2024.",

year = "2025",

month = feb,

doi = "10.1038/s41375-024-02487-1",

language = "אנגלית",

volume = "39",

pages = "529",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Springer Nature",

number = "2",

}

Sharman, JP, Egyed, M, Jurczak, W, Skarbnik, A, Pagel, JM, Flinn, IW, Kamdar, M, Munir, T, Walewska, R, Corbett, G, Fogliatto, LM, Herishanu, Y, Banerji, V, Coutre, S, Follows, G, Walker, P, Karlsson, K, Ghia, P, Janssens, A, Cymbalista, F, Woyach, JA, Ferrant, E, Wierda, WG, Munugalavadla, V, Yu, T, Wang, MH & Byrd, JC 2025, 'Correction: Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia (Leukemia, (2022), 36, 4, (1171-1175), 10.1038/s41375-021-01485-x)', Leukemia, vol. 39, no. 2, pp. 529. https://doi.org/10.1038/s41375-024-02487-1

Correction: Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia (Leukemia, (2022), 36, 4, (1171-1175), 10.1038/s41375-021-01485-x). / Sharman, Jeff P.; Egyed, Miklos; Jurczak, Wojciech et al.
In: Leukemia, Vol. 39, No. 2, 02.2025, p. 529.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Correction

T2 - Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia (Leukemia, (2022), 36, 4, (1171-1175), 10.1038/s41375-021-01485-x)

AU - Sharman, Jeff P.

AU - Egyed, Miklos

AU - Jurczak, Wojciech

AU - Skarbnik, Alan

AU - Pagel, John M.

AU - Flinn, Ian W.

AU - Kamdar, Manali

AU - Munir, Talha

AU - Walewska, Renata

AU - Corbett, Gillian

AU - Fogliatto, Laura Maria

AU - Herishanu, Yair

AU - Banerji, Versha

AU - Coutre, Steven

AU - Follows, George

AU - Walker, Patricia

AU - Karlsson, Karin

AU - Ghia, Paolo

AU - Janssens, Ann

AU - Cymbalista, Florence

AU - Woyach, Jennifer A.

AU - Ferrant, Emmanuelle

AU - Wierda, William G.

AU - Munugalavadla, Veerendra

AU - Yu, Ting

AU - Wang, Min Hui

AU - Byrd, John C.

PY - 2025/2

Y1 - 2025/2

N2 - Correction to: Leukemiahttps://doi.org/10.1038/s41375-021-01485-x, published online 01 January 2022 The wrong Supplementary file was originally published with this article; it has now been replaced with the correct file. The original article has been corrected.

AB - Correction to: Leukemiahttps://doi.org/10.1038/s41375-021-01485-x, published online 01 January 2022 The wrong Supplementary file was originally published with this article; it has now been replaced with the correct file. The original article has been corrected.

UR - http://www.scopus.com/inward/record.url?scp=85211774433&partnerID=8YFLogxK

U2 - 10.1038/s41375-024-02487-1

DO - 10.1038/s41375-024-02487-1

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.comment???

C2 - 39627506

AN - SCOPUS:85211774433

SN - 0887-6924

VL - 39

SP - 529

JO - Leukemia

JF - Leukemia

IS - 2

ER -

Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Flinn IW et al. Correction: Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia (Leukemia, (2022), 36, 4, (1171-1175), 10.1038/s41375-021-01485-x). Leukemia. 2025 Feb;39(2):529. doi: 10.1038/s41375-024-02487-1

Correction: Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia (Leukemia, (2022), 36, 4, (1171-1175), 10.1038/s41375-021-01485-x)

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this